AdKhabar’s Post

Waters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization

Waters introduces seamless HPLC/UPLC data bridge for light scattering, integrating essential instruments for large molecule characterization

Introducing High Throughput BioResolve Premier Columns for rapid analysis of large biomolecules. Reduce chromatography run-times by up to 5x and obtain vital information about monoclonal antibody critical quality attributes to make development decisions – fast. Learn more--> https://bit.ly/3VYuhTG

We're excited to present our newest resource for download, "Top 10 Tips for Successful Lateral Flow Assay Development." This guide condenses years of industry knowledge into critical tips, designed to help you refine your development process and secure accurate, dependable outcomes. #LFA #assaydevelopment

Inefficient biomolecule purifications are expensive for your lab. They lead to: - Lengthy purification processes that delay crucial research and development projects. - Prolonged operations that increase expenses, impacting budgets. - Sensitive biomolecules risking degradation due to extended purification. - Slower processes that limit the number of samples analyzed, affecting overall efficiency. - Potentially compromised purity and quality of final products. Introducing Sepax SRT-10C SEC media – a game-changing solution that offers: 🕒 Rapid processing: Accelerates purification, reducing run times. 📈 Enhanced purity: Maintains sample integrity and quality. 🔀Versatility: Suitable for a wide range of applications. Discover what Sepax SEC HPLC columns can do. Check out Sepax's specialized Biochromoatography Applications Database 👉 https://buff.ly/3QJXcXR #Biochromatography #LabEfficiency #SepaxSRT #Chromatography #Purification #LabManager

In this application note, learn how WuXi Biologics optimized upstream process development for bispecific antibodies by monitoring homodimer content using the Sartorius Ambr 15 Microbioreactor and the BioAccord LC-MS System. https://bit.ly/3xO8jsz #Bioprocess #WuXiBiologics #biotherapeutics

🖥️ Beat the summer heat with these upcoming July webinars! Check out our topics and register here: https://bit.ly/2RvfaSB 📍 July 4 | PFAS Determination in Matrices Beyond Water and Soil 📍July 11 | Nitrosamines in Drug Products 📍July 16 | HPLC Method Development 📍July 23 | mRNA Characterization

Some nice work by Coombes et al, looking at ssDNA assay for product purity 🛎Overview: Coombes et al have developed a novel method using ion pair reversed phase HPLC assay for ssDNA re-generation post PCR for selective enhancement of ligands by exponential enrichment (SELEX). But SELEX experiments often result in low yields of ssDNA aptamers and the ability to generate high-quality ssDNA in high yields from the dsDNA PCR products. 🎯 Summary: Coombes et al IP RP HPLC assay demonstrating significant advantages over existing affinity chromatography and nuclease digestion methods, for the purification of ssDNA . #massspectrometry #massspec #nucleotides #dna #lcms #hplc #chemistry #science #sciencecommunication #scienceandtechnology

In collaboration with Waters Corporation, Similis Bio demonstrated an automated Protein A purification and LC-MS analysis of bioreactor samples. The goal? To screen biosimilar monoclonal antibody (mAb) candidates and compare them to the innovator product during process development. The method proved sensitive and precise, allowing quantitative assessment of N-linked oligosaccharides and other post-translational modifications (PTMs). By evaluating these quality attributes early in clone selection, biopharmaceutical organizations can reduce subsequent development costs. The workflow also enables localization of Fab vs. Fc modifications. Read more about this innovative approach here: https://bit.ly/4dMci9f #Bioprocess #SimilisBio #biotherapeutics

I am so pleased today to be able to point to this publication detailing our use of a versatile differential equation comprising a normal-distribution-modified line for modeling certain analytical data of interest to pharmaceutical development. My sincere thanks to my co-workers Susannah Gaye and Morgan Crawford, professor Scoville of Ursinus College, and lastly to Dennis Peters (1937-2020) to whom this work is dedicated. https://lnkd.in/e9SVydg3 If you've read this post this far, may I ask you to consider the following? Have you ever collected or analyzed any measurement data which were ostensibly linear but sometimes had one or more data points (often at one extreme or another of a given range) which seemed to deviate variably and uncomfortably far away from a linear trend? Be honest--have you ever excluded one or more of those data points so you could do a simple linear regression through only the best looking values, even if a sub-set of the data really does cover the range you need? Certainly expediency has its place. After all, it is undeniably true that "the perfect is the enemy of the good". Still, there are times when a deeper examination of raw data is warranted. If and when such a time arrives for you, please look through this paper and remember that I, like Dr. Peters before me, would be delighted if you reached out. Be well, Lee